Despite a challenging 2024 for Boston’s life sciences market—marked by softening fundamentals and an oversupply of lab ...

Needham upgraded Boston Scientific Corp (NYSE:BSX) to “Buy”, saying competition from pulsed field ablation (PFA) rivals looks less intense for its key product than it was earlier feared, and citing ...